Bryce A. Kerlin, MD :: Nationwide Children’s Hospital, Columbus, Ohio

Contact Information

Hematology & Oncology
700 Children's Dr
Columbus, OH 43205 [ map ]
PH: (614) 722-3564
FX: (614) 722-3699
Email Me
The Research Institute at Nationwide Children's Hospital
700 Children's Drive
Columbus, OH 43205 [ map ]


Bryce A. Kerlin, MD is an Investigator in the Center for Clinical & Translational Research at Nationwide Children's Research Institute, Program Director for The Joan Fellowship in Pediatric Hemostasis-Thrombosis, Faculty in the Hematology/Oncology/BMT Division, and an Associate Professor of Pediatrics at The Ohio State University College of Medicine. Previously, he served for 10 years as Medical Director of the Nationwide Children’s Hemostasis & Thrombosis Center. His basic-translational research program is dedicated to elucidating the mechanisms by which coagulation enzymes interact with kidney cells to impact the health of glomeruli, the basic functional unit of the kidney. Diseases of glomeruli are amongst the leading causes of end-stage kidney disease, leading to the need for kidney transplant or long-term dialysis, and the 8th leading cause of death in the US. Current projects are focused on elucidating the mechanisms by which thrombin (a key enzyme in coagulation) induces or enhances glomerular injury in nephrotic syndrome, a major form of glomerular disease. His clinical-translational research program is focused on the translational epidemiology of pediatric thrombosis. Pediatric thrombosis is a serious complication, occurring in epidemic proportions, amongst children with complex, chronic illnesses and is associated with a 6–8-fold increase in the risk of death compared to children without thrombosis. Current projects are focused on (1) early detection of thrombosis through the use of software algorithms that mine electronic health records for signs and symptoms of thrombosis and (2) the elucidation of biomarkers and clinical characteristics associated with pediatric thrombosis to refine early detection and facilitate prompt institution of therapy. Dr. Kerlin is also the institutional principal investigator for several clinical trials investigating new diagnostic algorithms and treatments in hemostasis and thrombosis, including new medications for hemophilia, von Willebrand disease, and blood clots.


  • Male

Languages Spoken:

  • English

Research Interests

Research Center:

Research Funding*:

  • Patient and Family Support Group for Hemophilia Clinic, Hemophilia Foundation of Michigan/Cascade Hemophilia Consortium

Education and Training

Medical School

  • Medical College of Wisconsin

Post Doctoral

  • Blood Research Institute: The Blood Center of Southeastern Wisconsin


  • Medical College of Wisconsin and Children’s Hospital of Wisconsin

Undergraduate School

  • Purdue University

Medical School

  • Medical College of Wisconsin
    Date Completed: 05/18/1996


  • Phoenix Children's Hospital
    Date Completed: 06/30/1997


  • Phoenix Children's Hospital
    Date Completed: 06/30/1999


  • Medical College of Wisconsin
    Date Completed: 06/30/2002


  • Pediatrics


  • Hematology & Oncology


  • Pediatric Hematology Oncology

Date of Appointment at Nationwide Children’s Hospital:

  • 12/31/2004

Professional Experience


  • Director of Hematology, Nationwide Children's Hospital


  • Tumor Board,  Nationwide Children's Hospital


  • Pharmacy & Therapeutics, Nationwide Children's Hospital


  • Director, Nationwide Children's Hospital Hemophilia & Bleeding Disorders Program


  • Board Member, Ohio Bleeding Disorders Council


  • Pharmacy & Therapeutics Committee, Children's Hospital of San Diego


  • Medical Director, Hemophilia Association of San Diego County


  • Transfusion Medicine Committee, Children's Hospital of San Diego


  • Cancer Committee, Children's Hospital of San Diego


  • Director, San Diego Regional Pediatric Hemophilia Program


  • Tumor Board; Children's Hospital of San Diego


  • Tumor Board; Children's Hospital of Wisconsin


  • Director, Resident as Teacher Program; Phoenix Children’s Hospital/Maricopa Medical Center Pediatric Residency Program


  • Chairman, House Staff Social Committee; Phoenix Children’s Hospital/Maricopa Medical Center Pediatric Residency Program


  • Rheault MN, Wei C-C, Hains DS, Wang W, KERLIN BA, Smoyer WE. 2014. Increasing Frequency of Acute Kidney Injury Amongst Children Hospitalized with Nephrotic Syndrome Pediatric Nephrology.  Pediatric Nephrology. Vol. 29, no. 1. (January): 139-147.
  • KERLIN BA, Haworth K, Smoyer WE. 2013. Venous Thromboembolism in Pediatric Nephrotic Syndrome.  Pediatric Nephrology. Vol. Epub, no. June: 1-9.
  • Setty BA, O’Brien SH, KERLIN BA. 2012. Pediatric Venous Thromboembolism in the United States: A Tertiary Care Complication of Chronic Diseases.  Pediatric Blood & Cancer. Vol. 59, no. August: 258-264. PubMed ID: 22038730
  • Sladky JL, Klima J, Grooms L, KERLIN BA, O'Brien SH. 2012. The PFA-100® does not predict delta-granule platelet storage pool deficiencies.  Haemophilia. Vol. 18, no. 4. (July): 626-629. PubMed ID: 22226191
  • KERLIN BA. 2012. Current and Future Management of Pediatric Venous Thromboembolism.  Am J Hematol. Vol. 87, no. May: S68-S74. PubMed ID: 22367975
  • KERLIN BA Ayoob R, Smoyer WE. 2012. Epidemiology and Pathophysiology of Nephrotic Syndrome-Associated Thromboembolic Disease.  Clin J Am Soc Nephrol. Vol. 7, no. March: 513-520.
  • Kerlin,Bryce,A. 2011. Pulmonary morbidity of catheter-related pediatric venous thromboembolism: Old problem, new worry.  CRITICAL CARE MEDICINE. Vol. 39, no. 5. (May): 1234-1235.
  • Karsies TJ, Nicol KK, Galantowicz ME, Stephens JA, KERLIN BA. 2010. Thrombotic Risk of Recombinant Factor Seven in Pediatric Cardiac Surgery: A Single Institution Experience.  Annals of Thoracic Surgery. Vol. 89, no. 2. (February): 570-577.
  • Kerlin,Bryce,A. 2009. Thrombolysis for Pediatric Venous Thromboembolism: Is it Time for a Trial?.  PEDIATRIC BLOOD & CANCER. Vol. 53, no. 6. (December): 920-921.
  • KERLIN BA. 2009. Screening for Anemia. In Textbook of Pediatric Care. 1st ed. Edited by McInerny TK, Adam HM, Campbell D, Kamat DK, Kelleher KJ. Elk Grove Village, IL: American Academy of Pediatrics.
  • Mast KJ, Nunes ME, Ruymann FB, KERLIN BA. 2009. Desmopressin Responsiveness in Children with Ehlers-Danlos Syndrome Associated Bleeding Symptoms.  British Journal of Haematology. Vol. 144, no. January: 230-233.
  • Hyatt SA, Wang W, KERLIN BA, O'Brien S. 2009. Applying Diagnostic Criteria for Type 1 von Willebrand Disease to a Pediatric Population.  Pediatric Blood & Cancer. Vol. 52, no. January: 102-107.
  • Klopfenstein KJ, Clayton J, Rosselet R, KERLIN B, Termuhlen A, Gross T. 2009. Prevalence of Abnormal Bone Density of Pediatric Patients Prior to Blood or Marrow Transplant.  Pediatric Blood & Cancer. Vol. 53, no. January: 675-677.
  • KERLIN BA, Blatt NB, Fuh B, Zhao S, Lehman A, Blanchong C, Mahan JD, Smoyer WE. 2009. Epidemiology and Risk Factors for Thromboembolic Complications of Childhood Nephrotic Syndrome: A Midwest Pediatric Nephrology Consortuim (MWPNC) Study.  The Journal of Pediatrics. Vol. 155, no. January: 105-110. PubMed ID: 19394032
  • KERLIN BA. 2009. Thrombolysis for Pediatric Venous Thromboembolism: Is it Time for a Trial?.  Pediatric Blood & Cancer. Vol. 53, no. January: 920-921.
  • Sharathkumar A, Hardesty B, Greist A, Salter J, KERLIN B, Heiman M, Sulkin M, Shapiro A. 2009. Variability in Bleeding Phenotype in Amish Carriers of Hemophilia B with the C31008T Mutation.  Haemophilia. Vol. 15, no. January: 91-100.
  • Rose MJ, Nicol KK, Skeens MA, Gross TG, KERLIN BA. 2008. Congenital Amegakaryocytic Thrombocytopenia: the Diagnostic Importance of Combining Pathology with Molecular Genetics.  Pediatric Blood & Cancer. Vol. 50, no. January: 1263-1265.
  • Lo W, Zamel K, Ponnappa K, Allen A, Chisolm D, Tang M, KERLIN B, Yeates KO. 2008. The Cost of Pediatric Stroke Care and Rehabilitation.  Stroke. Vol. 39, no. January: 161-165.
  • Varga EA, KERLIN BA, Wurster MW. 2008. Social and Ethical Controversies in Thrombophilia Testing and Updates on Genetic Risk Factors for Venous Thromboembolism.  Seminars in Thrombosis and Hemostasis. Vol. 34, no. January: 549-561.
  • Davis RL, Mosesson MW, KERLIN BA, Canner JA, Ruymann FB, Brennan SO. 2007. Fibrinogen Columbus: a Novel gamma Gly200Val Mutation Causing Hypofibrinogenemia in a Family with Associated Thrombophilia.  Haematologica. Vol. 92, no. January: 1151-1152.
  • Nicol K, Swedan N, Moder P, Kahwash S, Rose M, KERLIN B. 2006. Hemolytic Anemia in a 5-Year-Old Child.  LabMedicine. Vol. 37, no. January: 746-748.
  • Savelli SL, Kerlin BA, Springer MA, Monda K, Thornton J, Blanchong CA: Recommendations for Screening for Thrombophilic Tendencies in Teenage Females Prior to Contraceptive Initiation.  Journal of Pediatric and Adolescent Gynecology 19:313-6, 2006. PubMed ID: 16873040
  • Savelli SL, KERLIN BA, Springer MA, Monda K, Thornton J, Blanchong CA. 2006. Recommendations for Screening for Thrombophilic Tendencies in Teenage Females Prior to Contraceptive Initiation.  Journal of Pediatric and Adolescent Gynecology. Vol. 19, no. January: 313-316. PubMed ID: 16873040
  • Loh KC, Willert J, Meltzer H, Roberts W, KERLIN B, Kadota R, Levy M, White G, Geddis A, Schiff D, Martin L, Yu A, Kung F, Spear MA. 2005. Temozolomide and Radiation for Aggressive Pediatric Central Nervous System Malignancies.  Journal of Pediatric Hematology/Oncology. Vol. 27, no. 5. (January): 254-258.
  • KERLIN BA, Cooley BC, Isermann BH Hernandez I, Sood R, Zogg M, Hendrickson SB, Mosesson MW, Lord S, Weiler H. 2004. Cause-Effect Relation between Hyperfibrinogenemia and Vascular Disease.  Blood. Vol. 103, no. 5. (January): 1728-1734.
  • Weiler H, KERLIN B, Lytle MC. 2004. Factor V Leiden Polymorphism Modifies Sepsis Outcome: Evidence from Animal Studies.  Critical Care Medicine. Vol. 32, no. 5 Supplement. (January): S233-S238. PubMed ID: 15118524
  • KERLIN BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, Joyce DE, Weiler H, Dhainaut J-F. 2003. Survival Advantage Associated with Heterozygous Factor V Leiden Mutation in Patients with Severe Sepsis and in Mouse Endotoxemia.  Blood. Vol. 102, no. 9. (January): 3085-3092.
  • Greenbaum LA, KERLIN BA, Van Why S, Punzalan RC, Trost BA, Pan CG, Scott JP. 2003. Concurrent Poststreptococcal Glomerulonephritis and Autoimmune Hemolytic Anemia.  Pediatric Nephrology. Vol. 18, no. 12. (January): 1301-1303.
  • Weiler H, Lindner V, KERLIN B, Isermann BH, Hendrickson SB, Cooley BC, Meh DA, Mosesson MW, Shworak NW, Post MJ, Conway EM, Ulfman LH, von Andrian UH, Weitz JI. 2001. Characterization of a Mouse Model for Thrombomodulin Deficiency.  Arteriosclerosis, Thrombosis, and Vascular Biology. Vol. 21, no. 9. (January): 1531-1537.
  • Woods G, KERLIN BA. Childhood Venous Thromboembolism. In Succinct Pediatrics. Edited by Feld L and Mahan JD.
  • Sharma R, KERLIN BA. Screening for Anemia. In American Academy of Pediatrics Textbook of Pediatric Care. Edited by Adam H, Campbell D, DeWitt T, Foy J, Kamat D, Baum R, Kelleher K, eds.

Awards, Honors and Organizations

  • Listed, Best Doctors in America

Pediacast Interview with Dr. Bryce Kerlin

Join Dr. Mike of Pediacast and Dr Bryce Kerlin as they describe Factor V Leiden. This relatively new disease was discovered in 1994 and results in the formation of blood clots where they aren't needed.

Pediacast with Dr. Mike Patrick

Listen now »

Listen to Dr. Kerlin on PediaCast

Factor V Leiden – PediaCast 175
Nationwide Children's Hospital
700 Children's Drive Columbus, Ohio 43205 614.722.2000